<Research>CLSA Adds CSPC PHARMA's TP to $13.8, Rating 'High-Conviction Outperform'

News Sharing

For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields

Receiver*

Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com

Your email address*

Content Sharing

<Research>CLSA Adds CSPC PHARMA's TP to $13.8, Rating 'High-Conviction Outperform'

CSPC PHARMA (01093.HK) will be a major beneficiary of the optimization of the volume-based procurement policy, CLSA opined in its report.In the CLSA's estimate, originator and ...

Reset

Send

The window will close in 5 seconds

<Research>CLSA Adds CSPC PHARMA's TP to $13.8, Rating 'High-Conviction Outperform'

Recommend

Positive

Negative

SHORT SELL

STOCK INFO

CSPC PHARMA (01093.HK) -0.090 (-1.565%) Short selling $101.38M; Ratio 17.683% will be a major beneficiary of the optimization of the volume-based procurement policy, CLSA opined in its report.

In the CLSA's estimate, originator and branded products usage will enjoy a substantial uplift as the volume-based procurement risk for the core product, "NBP", has been sharply reduced and current policies are inclined to grant hospitals greater prescription flexibility.

CLSA added its target price for CSPC PHARMA from $12 to $13.8 and gave it a "High-Conviction Outperform" rating.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-08 16:25.)

AAStocks Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.